CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Monte Rosa Therapeutics Presents Plans for Four Phase 2 Trial Starts in 2026

By Public Technologies
  • Monte Rosa Therapeutics expects cash runway into 2029, covering multiple anticipated Phase 2 studies across its three clinical programs.
  • Potential collaboration payments exceed $350 million over the next 24 months, following more than $400 million received over the past three years.
  • Novartis is conducting Phase 2a/b trials of MRT-6160 in Sjögren's disease and psoriatic arthritis; additional Phase 2 studies are expected.
  • MRT-8102 Phase 2 trials are planned for gout in Q4 2026, with coronary artery disease and hidradenitis suppurativa studies in H1 2027.
  • MRT-2359's Phase 2 trial in AR-mutant metastatic castration-resistant prostate cancer is ongoing, with an update expected in 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk